IP Library Granted Patent US 7,503,913
Granted Patent B2
US 7,503,913 · App. 11/249,757 · Granted Mar 17, 2009

Methods and compositions for use in perfusion applications

Assignee: BioTime, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,503,913
App. No.
11/249,757
Granted
Mar 17, 2009
Kind
B2
Abstract

Methods and compositions for use in perfusion applications are provided. In the subject methods, a subject or derivative thereof, e.g. isolated organ or tissue, is infused, perfused and/or transfused with at least two fluid compositions. The first fluid composition is a non-naturally occurring biological buffer free plasma-like solution and the second fluid composition is a fluid blood composition. In a preferred embodiment, an additional volume of the first solution, or a derivative thereof, is administered to the patient following introduction of the fluid blood composition. Also provided are kits and systems for performing the subject methods. The subject methods and compositions find use in variety of perfusion applications, including the treatment of hypothermic surgical applications, cryogenic procedures, and the like.

Claims (13)

1. A method of perfusing a subject, said method comprising:

sequentially introducing to said subject at least one quantity of first, second and third types of fluid compositions, wherein:

(a) said first fluid composition is a conventional biological buffer free, non-naturally occurring plasma-like solution comprising:

(i) electrolytes;

(ii) an oncotic agent;

(iii) and a dynamic buffering system;

(b) said second fluid composition is a fluid blood composition; and

(c) said third fluid composition is the same as said first fluid composition or is a derivative thereof;

to perfuse said subject.

2. The method according to claim 1 , wherein said electrolytes include: Na + , Mg 2+ , Ca 2+ , and Cl − .

3. The method according to claim 2 , wherein said non-naturally occurring plasma-like solution further includes K + .

4. The method according to claim 1 , wherein said oncotic agent is a polymer.

5. The method according to claim 1 , wherein said dynamic buffering system comprises an organic carboxylic acid, salt or ester thereof.

Assignments (2)
CHANGE OF NAME Recorded Jul 17, 2020
From: BIOTIME INC.
To: LINEAGE CELL THERAPEUTICS, INC.
Reel/Frame 053237/0463 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2006
From: SEGALL, PAUL E.; WAITZ, HAROLD D.; STERNBERG, HAL
To: BIOTIME, INC.
Reel/Frame 017147/0185 →
Continuity (3)
Continuation 1044539200 · May 23, 2003
Continuation 0924392100 · Feb 3, 1999
Related Publication 20060088606A1 · Apr 27, 2006